Tris Pharma Announces Approval of First-Time Generic of Methylphenidate Hydrochloride Oral Solution With Six Months Exclusivity

Wednesday, July 28, 2010 Drug News
Email Print This Page Comment bookmark
Font : A-A+



MONMOUTH JUNCTION, N.J., July 28 Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin® Oral Solution marketed by Shionogi Pharmaceuticals, Inc.

"Tris pursues selective generic opportunities, especially the difficult to formulate or complex formulations and this is a perfect example of Tris' capabilities," said Ketan Mehta, President and CEO of Tris Pharma. "Methylphenidate Hydrochloride, the active ingredient of many ADHD treatments is unstable in presence of water. Tris not only found a way to formulate this challenging product as an oral solution with requisite stability but did it rapidly by preempting Methylin's orange book patent listing and now launching the product 30 months sooner than it otherwise would have been."

This is the first-ever generic ANDA approved by the FDA for an immediate release methylphenidate hydrochloride oral solution. As part of the first approval, Tris is granted six-month regulatory exclusivity under Hatch-Waxman Act for both strengths of the product. Both strengths of the product, 5 mg/5 mL and 10 mg/5 mL are being launched simultaneously and distributed by Breckenridge Pharmaceutical, Inc.

About Tris Pharma, Inc.

Tris Pharma is a specialty pharmaceutical company focused on drug delivery technologies based products including difficult-to-formulate or complex generic products. Through its OralXR+ technology platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse platform provides abuse- deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey.

For more information visit www.trispharma.com

Methylin is a registered trademark of Mallinckrodt, Inc.

SOURCE Tris Pharma, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store